The University of Chicago Header Logo

Connection

Russell Z. Szmulewitz to Maximum Tolerated Dose

This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Maximum Tolerated Dose.
Connection Strength

0.120
  1. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257.
    View in: PubMed
    Score: 0.040
  2. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 11; 79(15):1752-1761.
    View in: PubMed
    Score: 0.040
  3. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6309-6319.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.